The systematic use of patient-reported outcome measures (PROMs) has been advocated as an effective way to standardize cancer practice. Yet, the question of whether PROMs can lead to actual improvements in the quality of patient care remains under debate. This review examined whether inclusion of PROM in routine clinical practice is associated with improvements in patient outcomes, processes of care, and health service outcomes during active anticancer treatment. 
INTRODUCTION
Anticancer treatments have brought about definite advances in patient survival rates.
1 However, treatment is associated with significant toxicity that is potentially life-threatening, 1 and can often result in poor treatment adherence, impaired quality of life (QoL), and mortality. 2, 3 Systematic monitoring is crucial to detect problems, to address needs of patients, and to plan care. 4 Using patient-reported outcome measures (PROMs), "measurements of any aspect of a patient's health status that come directly from the patient," 5 facilitates a systematic and comprehensive approach to patient assessment and identifies problems that are often overlooked within routine practice. Regularly collecting PROM data is an effective way to standardize practice and improve patient management. 4 Nevertheless, the question of whether PROMs can improve the quality of patient care, and whether this relates both to health professional engagement with them and to the system guidelines in place to guide response, remains under debate. Given the costs associated with collecting PROMs, evidence of their effect on patient outcomes (POs), processes of care (PoCs), and/or health service outcomes (HSOs) is needed.
condition. Only seven RCTs were rated as low risk on both the randomassignment generation process and allocation-concealment bias. 17, 20, [26] [27] [28] [29] 41 Conversely, all non-RCTs were consistently rated as high risk. With the exception of three RCTs, 21, 22, 40 performance bias was rated as high for all CTs given that blinding on the HP level was not feasible. With the exception of seven CTs, 18, 25, [28] [29] [30] 40, 41 risk of detection bias was also deemed high or unclear. Ten CTs were rated as high risk regarding attrition-related bias. [18] [19] [20] 24, 27, 33, 35, [38] [39] [40] [41] [42] Selective outcome reporting bias was predominantly unclear (n ϭ 18; 75%). Additional sources of bias interfered with 15 CTs. Most frequently, authors were unclear as to whether HPs who received patient feedback actually used it during consultations.
Outcomes Evaluation
POs and/or PoCs were reported as primary outcomes in 21 CTs (87.5%) and 19 CTs (79.2%), respectively; however, intervention effects on HSOs were only scarcely investigated (Table 2 and Table 3) . 20, 22, 27, 30, 42 Eighteen CTs evaluated the effects of interventions in the long term (Ͼ 8 weeks), with follow-up assessments ranging in number from two to four or more that were conducted for up to 12 months (but mainly Յ 6 months) after baseline assessment.
Patient Outcomes
Physical symptoms. Overall, positive effects with reduced symptom prevalence or severity were reported in seven CTs (six RCTs), mainly clinically and less frequently statistically significant. ES ranged widely and were mainly small-tomoderate in terms of intervention effects on physical symptom prevalence (d ϭ 0.01 to 0.75), physical symptom severity (d ϭ 0.0 to 0.44), psychological symptom prevalence (d ϭ 0.07 to 0.15), psychological symptom severity (d ϭ 0.01 to 0.30), or psychological symptom distress (d ϭ 0.09 to 0.42; Appendix Table A3 ). Across CTs, patients in the experimental group reported greater reductions in symptomthreshold events and symptom interference with functioning, 40 severity of menopausal symptoms and sexual dysfunction, 22 frequency of constipation and vomiting, 25 incidence of pain 37 or fatigue, 41 debilitating symptoms, 18 and distress associated with symptoms/problems 32,41 compared with those in the control group, irrespective of cancer type or stage.
Quality of life. Survivors of breast cancer, 22 patients with nonlocalized breast cancer or colorectal cancer, 23 and groups of patients with mixed cancer diagnoses at an advanced stage 21, 31, 42 or at various clinical stages 24, 28 had no significant postintervention effects in nine CTs (Table 2; Appendix Table A3 ). In terms of overall QoL, ES ranged from 0.04 to 0.59, but were mainly small in magnitude. Nevertheless, rates of diseased QoL were reduced in women with breast cancer 6 months after surgery in the experimental group compared with the control group (d ϭ 0.35). 26 Among patients with lung cancer, QoL scores deteriorated in the experimental group more than in the standard-care group over the 16 weeks of observation. 29 Velikova et al 38 reported improvements in patient QoL scores at treatment initiation that were influenced by whether QoL was actually discussed during consultations. 38 Psychological symptoms. Results were generally unsupportive of significant postintervention effects on anxiety and/or depression regardless of whether direct real-time 18, 23 or indirect 20 patient feedback was made available to HPs. This was evident despite overall reductions in psychological distress over time. 27 Similarly, McLachlan et al 28 found no overall intervention effects on depression scores, but the subgroup of patients classified as moderately or severely depressed benefitted more from the intervention. Where significant improvements in anxiety or depression were reported, 42 these were small-tomoderate in magnitude (d ϭ 0.15 to 0.42) and not universal across all assessment PROMs.
Supportive care needs. Five CTs provided generally unclear evidence; despite some small-to-moderate ES (d ϭ 0.16 to 0.58) across domains of need, these were not always in favor of the experimental group (Appendix Table A3 ). The PROM intervention was no better than usual care in tackling needs of patients in two trials. 18, 23 We found statistically significant between-group differences in 13 of 19 categories of perceived need 32 and sexual health concerns (d ϭ 0.49) 22 in favor of the experimental group among patients with hematologic malignancies 32 and breast cancer, 22 respectively. In a non-RCT, patients receiving routine psychological screening reported more psychological, information, and physical/daily living needs, but not sexuality needs, at 6 months postbaseline compared with the unscreened cohort.
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Processes of Care
Medical decisions made/advice given/changes in treatment/referrals made. Despite being the outcomes most frequently investigated (Table 3) , evidence (n = 23) (n = 13) (n = 1) (n = 1) (n = 5) (n = 1) (n = 2) Abbreviations: AR, attrition rate; ATR, active treatment; BT, biological therapy; C, control; CATI, computer-assisted telephone interview; CT, chemotherapy; d, days; EM, educational materials; ESRA-C, Electronic
Self-Report Assessment-Cancer; f/u, follow-up; GP, general practitioner; h, hours; HP, health care professional; HT, hormonal therapy; I, intervention; m, months; MD, medical; NA, not applicable; NR, not reported;
O, oncologist; PROM, patient-reported outcome measure; PSC, palliative supportive care; QoL, quality of life; RCT, randomized controlled trial; RR, response rate; RT, radiotherapy; SC, supportive care; SCT, stem-cell transplantation; SRG, surgery; TCW, telephone caseworker; TM, telephone monitoring; UK, United Kingdom; US, United States; w, weeks; y, years.
‫ء‬
Percentages valid for total sample. †Sample sizes of patients as randomly assigned (RCTs) and consented (non-RCTs) at baseline. ‡Physicians, rather than patients, were randomly assigned. §Estimated as the total of 3 TCWs and 119 O/GPs. ¶Group sizes were not reported.
Articles are based on data from the same study; different sample sizes and outcomes are evaluated in each article.
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www.jco.org of intervention effects on actions taken as a result of PROM feedback becoming available to clinicians remains generally ambiguous (Appendix Table A4 ). No significant intervention effects were reported in the number of patients referred to psychosocial care 19, 20, 36 or in clinical actions taken. 21, 24, 31 Although at 3 months after the intervention women with breast cancer in the experimental group were offered counseling and psychotherapy services more often, at 6 months this difference disappeared.
26 When PROMs were used to increase physician awareness of patients' levels of pain, a significant change (d ϭ 0.41) in analgesic prescription patterns was found to favor the experimental group. 37 During treatment for chest malignancies, significantly more patients in the experimental group received diagnostic and therapeutic services for emotional and social concerns, 30 but numbers of QoL-related actions taken per patient were similar across study groups.
34
Patient satisfaction with care and/or communication with team. Regardless of study condition, patient remarks on satisfaction with care and/or communication with HPs were generally positive. 19, 21, 24, 28, 29, 31, 34, 39, 40 Though eight CTs 19, 24, 28, 29, 31, 34, 40 failed to show significant intervention effects (Appendix Table A4 ). In the studies in which postintervention gains were reported, the positive effects referred to greater satisfaction with emotional support in the palliative chemotherapy context, 21 greater satisfaction with patients receiving follow-up from oncology nurses rather than general practitioners (though differences from usual care were not examined), 23 and enhanced communication with physicians in the outpatient setting compared with standard care.
39
Patient outcomes discussed during consultation. Regardless of patients' cancer type, significant postintervention increases over time in the frequency of discussions pertinent to patient outcomes during consultations were recorded. 35, 38 The odds of such outcomes being discussed seemed to depend on whether these were reported at a level indicating a problem.
17 Though emotional problems tend to be discussed more often during consultations in the experimental group, 19 social and sexual functioning issues may be those on which the intervention proves most effective.
17 Still, the overall patientphysician communication may not significantly improve. 19 In the lung cancer population, significantly more symptoms were discussed and addressed during consultations, 34 but intervention effects on QoL discussions fell short of significance. Much greater intervention effects were reported in the context of palliative chemotherapy (Appendix Table A4 
24
HP acceptability/evaluation of intervention. Where addressed, intervention acceptability was moderate to high across all CTs (Table 2) , with rates of perceived usefulness ranging from less than 50% to 68%. HPs felt obtaining an overall assessment of the patient was more helpful 21, 38, 39 to identify issues of concern 17, 19, 21, 38 and to guide discussions with patients [17] [18] [19] 24 rather than in communicating with patients 17, 19 and in managing and enhancing the care provided.
18,38 Yet, in two similar CTs, all physicians 21 and nurses 24 agreed that the intervention facilitated patient-clinician communication. The ability of HPs to identify psychosocial concerns 19, 21 and address difficult subjects such as sexuality issues 24 was also enhanced. Although actual changes in HP communication styles may not be seen even following the intervention, 19 physicians 21, 39 and nurses 24 seem willing to continue using the PROM summary in everyday practice. Nurses significantly more frequently found PROM interventions beneficial 17 and felt that use of relevant information resulted in more efficient use of their time.
Patient satisfaction with intervention. Overall satisfaction with intervention was evident for at least 80% of patients. 40, 42 The PROM interventions were seen as easy to use 40 and a useful way for patients to describe their situation 39 and communicate important information to HPs. 19 Patients expressed their willingness to continue using it in routine care. 39, 40 However, in the Kornblith et al 42 CT, percentages of patients rating the PROM intervention as very or extremely helpful in coping with an important problem were notably low and favored the control rather than the experimental group (37% v 14%; d ϭ 0.69). More than 83% of patients regarded the PROM content important for them and its use necessary for all patients receiving treatment.
19,36 Moreover, almost all patients (93%) appreciated having been asked about their emotional well-being during treatment. 36 In the palliative care setting, patients agreed that the summary profile enhanced their physician's or nurse's awareness of their health problems (79% to 89%), and that it would be useful as a standard part of their consultations (87% to 99%).
21,24
HP awareness of patient outcomes. In the context of palliative chemotherapy, no intervention effects were reported on the magnitude of patientphysician agreement about patients' physical, emotional, and social well-being and daily activities (d ϭ 0.09 to 0.50; Appendix Table A4) . 21 The only exception was greater agreement in ratings of social functioning in the experimental group, but this applied only to the subgroup of patients who reported moderate-to-severe problems. 21 Oncology nurses' awareness of daily activities, pain, and QoL was significantly higher in the experimental group during the fourth patient visit. 24 Positive intervention effects were reported in patient care documentation in the medical records of patients being treated for hematologic malignancies 32 and in the number of QoL issues charted in records of patients with lung cancer.
34
Timing of referrals. One RCT revealed that PROM feedback resulted in significantly earlier postconsultation referral of patients in the experimental versus the control group by an average of three weeks. 19 In a sequential cohort trial of patient-distress screening, average time to referral in the unscreened cohort was 14 days compared with a considerably earlier referral of only 5 days in the screened cohort.
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Health Services Outcomes
Only five CTs explored the effects of the routine use of PROMs on HSOs (Table 3; Appendix Table A5 ), namely, numbers of patients making use of health services 20, 22, 42 and frequency of contacts with health professionals.
27,30
Ganz et al 22 reported only minimal use of services after referral to psychosocial care in women with breast cancer; whereas prevalence of cases in which patients sought professional help was similar irrespective of study group among newly diagnosed patients with lung cancer and breast cancer. 20 Among patients with advanced breast, colorectal, or prostate cancer, use of mental health services at 6 months after intervention was equally minimal regardless of study condition (P ϭ .34). 42 In terms of frequency of patient-HP contacts, positive intervention effects were found among women with breast cancer 27 but not among patients with chest malignancies.
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DISCUSSION
We found only tentative evidence regarding the effectiveness of PROM interventions to improve the quality of care provided to patients receiving active anticancer treatments. We used strict systematic methods during identification 12 and risk-of-bias appraisal 13 of all trials included here. We included 24 CTs, which investigated a wide range of outcomes, thus producing a disparate set of data and indicating lack of consensus around the role of PROMs and the range of outcome measures in clinical practice. Evidence suggests that, irrespective of the context of chronic illness, the impact of PROMs on POs is weak. 9, 44 Where possible, we calculated ES in an attempt to quantify the magnitude of these effects, and our findings indicate inconsistencies in the overall significance (statistical or clinical) and low-tomoderate intervention effectiveness. Importantly, efficacy of the CTs reviewed seems low, confirming findings from previous reviews. 5, 9, 44 Contrary to the limited evaluation of HSOs, PoCs were the most frequently investigated outcomes in our sample of trials. Mixed findings emerged regarding medical decisions made or actions taken by HPs as a result of the availability of PROM data. Changes in HP practices fell short of significance and, where such changes were documented, 30,37 the associated ES were still small. It is unclear whether limited referral options, additional subjective HP assessments, or other health careϪrelated factors influenced the use of PROMs in practice. Patient satisfaction with care did not improve significantly, possibly owing to the presence of ceiling effects. Moreover, achievable improvements in patient communication with HPs, especially regarding emotional health issues, were documented, but ES were quite small. Somewhat greater ES can be proposed with regard to the actual discussion of POs during consultations, particularly physical symptoms, but not necessarily around supportive care needs.
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Fewer than 30% of the CTs addressed the important question of whether the use of PROM interventions appeals to patients and HPs. Though HPs may view PROMs as useful toward a more comprehensive or systematic assessment, communication is not always enhanced. In addition, there is still limited (albeit positive) evidence about whether HPs wish PROMs to become routine practice. Whether patients can comply with the systematic use of PROMs during treatment and encounters with the clinical team is equally unclear. Despite limited evidence, including electronic systems to enhance data collection and management, as well as use of clinical algorithms to support clinicians in the management of identified areas for intervention, might potentially increase adherence to and acceptability of PROMenhanced clinical assessments.
Current data also suggest that patient physical symptoms and distress may be more amenable to improvement after PROM interventions than QoL, supportive care needs, or psychological symptoms. Even with the exception of the few studies that examined the use of health services by patients or contacts with HPs, important aspects of an intervention's applicability, such as patient safety or costeffectiveness and cost-efficiency, are yet to be included as potential end points to encourage policy makers to consider making changes in the way cancer care is provided. Despite this lack of evidence, the Department of Health in England is aiming to extend the use of PROMs in a wider range of conditions in that country's National Health Service, 45 which would include cancer care.
Finally, measurement bias interfering with the effects of PROM interventions documented in this review should also be considered. Arguably, not all tools used in the delivery of interventions were originally developed as PROMs, which might have affected the reliability of reported outcomes and their subsequent interpretation. In addition, the psychometric robustness of the PROMs used to deliver and/or evaluate intervention effects is questionable and might have interfered with its ability to capture the actual magnitude of such effects. Similar comments can be made regarding sources of bias, such as absence of randomization or uncertainty about whether clinicians did use information generated by PROMs during consultations, which may have further affected the trials' internal and external validity and adversely affected credibility of available evidence.
Our search strategy was purposefully inclusive, with an aim to include all relevant literature. However, it was limited to the most common bibliographic databases, as well as to peer-reviewed articles and reports published in the English language only. In addition, the gray literature was not searched. Owing to the vast heterogeneity in the studies included, a meta-analytic synthesis was not feasible. Unavailability of data also prevented us from calculating ES for some of the included studies. However, such cases were equally distributed across statistically significant and nonsignificant findings or across the different outcome categories; hence, we are confident that the associated reporting bias has not greatly affected our conclusions.
More research is necessary on the effects of PROM interventions on health outcomes across different types of cancers and treatment modalities. The use of PROMs in clinical practice seems to be most effective in increasing patient satisfaction with communication about emotional concerns. Discussion of POs during consultations may increase and, in some studies, is associated with improved symptom control, increased supportive care measures, and patient satisfaction. Additional patient-related outcomes could be usefully addressed in future trials, including perceived self-care self-efficacy, social activity, work limitations, or survival. Patients and HPs are willing to engage in the routine use of PROMs during anticancer treatment. However, it is paramount that PROM intervention implementation is effective and incorporates strategies that increase patient adherence to the actual use of PROMs and HP engagement in the active incorporation of PROM feedback during encounters with patients. 44 Consensus is also required on the standardization of PROMs to be used in future trials. Finally, dedicated research is required to support the cost-effective use of PROMs in clinical practice regarding patient safety, clinician burden, and health-services usage. This is an important area of consideration, particularly in times of increasing demands on health care. NOTE. Negative ES denote more favorable outcomes (eg, less severity or better scores) for the intervention group, and vice versa. ES were not calculated for controlled trials that reported pre-intervention between-group differences in the outcome in question, or where no relevant data were available. Where data were available, but no such baseline comparisons were performed/stated, baseline scores/percentages were compared using two-tailed independent sample t tests, thus ensuring that postintervention scores were not a result of preintervention differences. When studies reported results at more than one time point, the final time point was used, thus ensuring independence of data; hence, each study contributed no more than one ES for a specific outcome. 14 For studies with more than one experimental group, separate ES were calculated if different intervention PROMs were used; however, if the same intervention PROM was used, one ES was calculated based on pooled experimental versus control effects. If a study indicated that the effect was nonsignificant but no statistics were provided, ES was entered as zero.
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Abbreviations: ES, effect sizes; PROM, patient-reported outcome measure; QoL, quality of life.
‫ء‬
ES calculations were performed only in those studies for which enough data were available. †Where no 95% CIs are reported, not enough data were available to calculate them. ‡Based on P values (P Ͻ .05) and direction; ϩ favors the intervention group (P Ͻ .05); Ϫ favors the control group (P Ͻ .05); Ϯ represents P Ն .05. NOTE. Negative effect sizes denote more favorable outcomes (eg, more frequent use of service or more contacts) for the intervention group and vice versa. ES were not calculated for controlled trials that reported preintervention between-group differences in the outcome in question or where no relevant data were available. Where data were available but no such baseline comparisons were performed or stated, baseline scores/percentages were compared using two-tailed independent sample t tests, thus ensuring that postintervention scores were not because of preintervention differences. When studies reported results at more than one time point, the final time point was used, thus ensuring independence of data. Hence, each study contributed no more than one ES for a specific outcome. 14 For studies with more than one experimental group, separate ES were calculated if different intervention PROMs were used; however, if the same intervention PROM was used, one ES was calculated based on pooled experimental versus control effects. If a study indicated that the effect was nonsignificant but no statistics were provided, ES was entered as zero.
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Abbreviations: ES, effect size; PROM, patient-reported outcome measure.
‫ء‬
ES calculations were performed only in those studies for which enough data were available. †Based on P value (P Ͻ .05) and direction; ϩ (P Ͻ .05 favors intervention group); Ϫ P Ͻ .05 favors control group); Ϯ (P Ն .05).
